Manfred Koegl

Title: Manfred Koegl: Innovator in Oncological Treatments

Introduction

Manfred Koegl is a notable inventor based in Moedling, Austria. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target oncological diseases. His work is characterized by a commitment to advancing medical science through innovative solutions.

Latest Patents

Koegl holds a patent for "6-amino-quinolinone compounds and derivatives as BCL6 inhibitors." This invention encompasses compounds of a specific formula, wherein the groups R to R, X, Y, and W have defined meanings as stated in the claims and specification. The patent details their use as inhibitors of BCL6, as well as pharmaceutical compositions that contain these compounds. These compounds are particularly valuable as medicaments for the treatment and prevention of oncological diseases.

Career Highlights

Manfred Koegl is associated with Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. His work at the company has been instrumental in the development of innovative treatments that address critical health challenges. With a focus on research and development, Koegl has contributed to the advancement of therapeutic options for patients.

Collaborations

Koegl has collaborated with esteemed colleagues such as Steffen Steurer and Georg Dahmann. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries in the pharmaceutical field.

Conclusion

Manfred Koegl's contributions to the field of oncology through his innovative patents and collaborations highlight his role as a key figure in pharmaceutical research. His work continues to pave the way for new treatments that can significantly impact patient care.